Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975700 | 0.79 | PTGS1 (0.39) | EGLN1KDM4ESMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1809791 | 0.73 | TP53 (0.47) | EGLN1NPSR1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL1810341 | 0.72 | EGLN1 (0.40) | LCKEGLN1NPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL1809247 | 0.72 | KDM4E (0.47) | LCKEGLN1KDM4ELMNAALDH1A1 | |
| SCHEMBL1810167 | 0.72 | EGLN1 (0.40) | LCKEGLN1NPSR1KDM4CKDM4E | |
| SCHEMBL31636929 | 0.71 | LCK (0.38) | LCKNPSR1KDM4CKDM4ELMNA | |
| SCHEMBL31016818 | 0.70 | LCK (0.38) | LCKNPSR1KDM4CKDM4ESMN1; SMN2 | |
| SCHEMBL31636618 | 0.70 | LCK (0.38) | LCKEGLN1NPSR1KDM4CKDM4E | |
| SCHEMBL1971895 | 0.70 | PTGS1 (0.39) | KDM4ESMN1; SMN2HSD17B10MAPTALDH1A1 | |
| SCHEMBL31017018 | 0.70 | EGLN1 (0.41) | LCKEGLN1NPSR1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000006-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8703795-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1866318-B1 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN INC (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1866318-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094292-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | LCK 3555/4885EGLN1 7/4885NPSR1 2300/4885 |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | HIF1AN, HIF1A, EGLN2 | LCK 3555/4885EGLN1 7/4885NPSR1 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.